Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed malignant pulmonary neoplasm
• New lung lesion(s) with definitive clinical and imaging features of primary or metastatic disease allowed
• * Imaging findings compatible with localized treatment failure after prior cryotherapy allowed
• Malignant pleural effusion allowed provided it is associated with a distinct measurable pulmonary mass amenable to cryotherapy
• Metastatic disease must meet all of the following criteria:
• * Primary tumors have been resected or have been deemed controlled by other therapies
• * No other widespread metastases evident (e.g., multiple hepatic or brain metastases)
• Each pulmonary mass must be amenable to CT-guided percutaneous cryotherapy approach
• No more than 5 targeted masses for study therapy
• * Target mass defined as pulmonary, hilar, mediastinal, and/or chest wall mass \> 1 cm, but \< 10 cm in average diameter
• Unresectable disease by surgical consultation OR patient refused surgical options
• Nonenhanced and enhanced CT scan required within the past 6 weeks done at 4-5 mm increments with available soft tissue and mediastinal windows to assess size and extent of all thoracic tumors
• * PET scan required within the past 6 months noting the correlation with the above CT locations, if not already obtained by a combined PET/CT scanner
• PATIENT CHARACTERISTICS:
• Karnofsky performance status (PS) \> 60-100% OR WHO/ECOG/Zubrod PS 0-2
• FEV\_1 \> 30% of predicted
• DLCO \> 40% of predicted
• Platelet count ≥ 70,000/mm\^3
• INR \< 1.5
• No uncontrolled coagulopathy or bleeding diathesis
• Not pregnant or nursing
• Negative pregnancy test
• No serious medical illness, including any of the following:
• * Uncontrolled congestive heart failure
• * Uncontrolled angina
• * Myocardial infarction
• * Cerebrovascular event within 6 months prior to study entry
• No medical contraindication or potential problem that would preclude study compliance
• PRIOR CONCURRENT THERAPY:
• At least 7 days since prior aspirin and aspirin-like medications
• At least 3 days since prior warfarin, clopidogrel bisulfate, or similar compounds
• No concurrent drugs causing bleeding tendencies (e.g., aspirin, warfarin, or clopidogrel bisulfate)
• No concurrent participation in other experimental studies